MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO.

The Company has granted the underwriter a 45-day option to purchase up to an additional 450,000 shares of its Class A Ordinary Shares at the Offering Price, representing 15% of the Class A Ordinary ...

Insulin resistance is a metabolic condition in which the body's cells no longer respond effectively to insulin, the hormone ...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a months-long roadshow across central ...

About the TUPELO Trial Design (REC-4881) The Phase 1b/2 TUPELO trial is evaluating the safety, tolerability, pharmacokinetics ...

Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year. Designation underscores need for therapies to treat severe hypoglycemia in the onco ...

Live webcast links for the fireside chats will be available at https://investors.werewolftx.com/news-and-events/events. Archived replays will be available for approximately 90 days following the ...

Nexalin intends to use the net proceeds from the offering for working capital and other general corporate purposes, including sales and marketing activities, product development and capital ...

An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report ...

Delivered record total revenue of $15.5 million on the strength of continued ASP expansion and AVISE CTD test volume growth. Expanded AVISE CTD trailing twelve-month ASP to $419, an increase of $42 ...